Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) (FMT-ELIMINATE)
Phase II Trial of Healthy-donor Derived Full-spectrum Microbiome Therapeutic MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) (FMT-ELIMINATE)
Sponsor: Cures Within Reach
This PHASE2 trial investigates Immune-mediated Colitis (IMC) and Immune-related Dermatitis and is currently actively recruiting participants. Cures Within Reach leads this study, which shows 7 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2025 — Feb 2026 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2024 — Feb 2025 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 2 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cures Within Reach
- Diwakar Davar
- Stanley Marks Fund for Cancer Research
For direct contact, visit the study record on ClinicalTrials.gov .